ClinicalTrials.gg
Not yet recruitingNCT07042113611Updated Jun 27, 2025

A Study of Two Different Formulations of 611 in Healthy Adult Subjects in China

A Phase 1 interventional study of new formulations of 611 and existing formulations of 611 in Atopic Dermatitis, sponsored by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.. Not yet recruiting at 2 sites in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-27.

Sponsored by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (part of 3SBio Inc.) · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2026, 10 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 207 studies in Dermatitis, Atopic with a site in China — 65 open to participants now, 83 under way, 29 of them phase 3. Dermatitis, Atopic · China.

Planned enrollment
86th of 191
180 · median 163
Started
2025
with 33 others
Phase 1
39 of 207
15 open now
Primary completion
2026-01
later than 18 of 82 live
Registered
151st of 207
by date
Lead sponsor
8 of 207
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Among the 207 studies in Dermatitis, Atopic with a site in China, this one is the 86th largest by planned enrollment of the 191 interventional ones that give a count, is one of 34 that started in 2025, is one of 39 in phase 1, reaches primary completion later than 18 of the 82 other live ones, and was the 151st registered.

Dermatitis, Atopic

1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

65 of the 207 studies in Dermatitis, Atopic with a site in China are open now. Recruiting first, the newest first:

60 more — sign in →

All 65 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 207 studies in Dermatitis, Atopic with a site in China, or all of them as a file.
02

Study summary

The main purpose of this study is to compare two different formulations (mixtures) of 611 in healthy participants. This study will compare how much of each formulation gets into the blood stream.

Read the detailed description

This study is a randomized, open-label, parallel-designed comparative pharmacokinetic study to evaluate the biosimilarity between the formulations of 611.A total of about 180 healthy adult subjects in China were planned to be included, and the qualified subjects were randomly stratified according to the research center, body weight (≥65kg, \<65kg), and randomly assigned to the test preparation group and the reference preparation group at a ratio of 1:1, and received a single subcutaneous injection of 300 mg of the experimental drug according to their group. Blood was collected on D1 and D2, D3, D4, D5, D6, D7, D8, D15, D22, D29, D43 and D57 after administration, respectively.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willingness to provide written for the study.
  2. Male or female subjects, age 18-45 years older.
  3. Within (BMI) range 19.0 to 26.0 kilograms per square meter (kg/m²).
  4. The results of vital signs, physical examination, laboratory tests, , chest X-ray and other examinations during the screening period are normal or judged to be abnormal by the investigator and have no clinical significance.
  5. Males and females of non-.

Exclusion criteria

Exclusion Criteria:

  1. History of severe allergies or allergies to 611 and any of its components;
  2. Previous or current disease that may affect the safety of the subject's participation in the trial or the in vivo process of the trial drug;
  3. Any history of VKC and AKC;
  4. History of drug abuse within 2 years prior to screening;
  5. Alcoholism within 3 months prior to screening;
  6. Those who smoke more than 5 cigarettes per day within 3 months before screening or cannot give up smoking during the period from signing the of the subject to leaving the group;
  7. Those who have consumed more than 1L of strong tea, coffee and/or caffeinated beverages per day within 3 months before screening, and who have ingested chocolate or any food or drink containing caffeine, theophylline, theobromine or alcohol within 48 hours before the study administration;
  8. Have active tuberculosis;
  9. Presence of active infection requiring systemic treatment prior to screening or dosing;
  10. Those who have used any prescription drugs, over-the-counter drugs, vitamin products or Chinese herbal medicines within 4 weeks or 5 half lives (whichever is longer) before dosing, or those who may need to receive other drugs during the trial;
  11. Participated in the clinical trial of any drug or device within 3 months or 5 half-lives before dosing;
  12. Receipt of any marketed or biologic within 3 months or 5 half lives prior to dosing;
  13. or live attenuated vaccine within 2 months prior to dosing or planned administration during the study;
  14. Previous use of any IL-4Rα target drugs;
  15. Pregnant or lactating females;
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    Tested preparation group

    Healthy subjects will receive new formulations of 611 300mg once

    Drug: new formulations of 611

  • Experimental
    Reference preparation group

    Healthy subjects will receive existing formulations of 611 300mg once

    Drug: existing formulations of 611

Interventions

  • Drugnew formulations of 611

    Subjects will receive new formulations of 611 300mg once subcutaneous injection on D1

  • Drugexisting formulations of 611

    Subjects will receive existing formulations of 611 300mg once subcutaneous injection on D1

06

What researchers measure

Primary outcomes

  1. Cmax

    Time frame: 57 days

  2. AUC

    Time frame: 57 days

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2025; primary completion for Jan 2026, 6 months later.

Of 114 industry-sponsored phase 1 interventional studies under Dermatitis, Atopic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's planned 6 months is below that.

Counting every sponsor, half of 131 studies reached it within 13 months; a quarter within 5 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2025
First posted
Jun 27, 2025
StartEst.
Jul 2025
Primary completionEst.
Jan 2026
CompletionEst.
Jan 2026
Last update
Jun 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07042113
Responsible party
Sponsor
First posted
Jun 27, 2025
Start date
Jul 2025 (estimated)
Primary completion
Jan 2026 (estimated)
Completion
Jan 2026 (estimated)
Last update
Jun 27, 2025

Study contacts

Qinghong Zhou
Contact
zhouqinghong@3sbio.com
+86 18911301578

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion